Table 3.
Multivariate analysis for OS after RR-AML
| Variable | HR (95% CI) | P value |
|---|---|---|
| Age (<60 vs ≥60 years) | 1.20 (0.82-1.76) | 0.35 |
| Treatment intensity post-RR-AML | ||
| IT vs BSC | 0.26 (0.16-0.43) | <0.001 |
| NIT vs BSC | 0.32 (0.23-0.48) | <0.001 |
| IT vs NIT | 0.80 (0.38-1.7) | 0.56 |
| Best response pre-RR-AML | ||
| CR <12 months vs NCR | 0.87 (0.6-1.25) | 0.44 |
| CR ≥12 months vs NCR | 0.55 (0.33-0.92) | 0.03 |
| CR ≥12 months vs <12 months | 0.64 (0.38-1.05) | 0.08 |
| ELN risk score | ||
| Favorable vs intermediate | 1.42 (0.8-2.5) | 0.23 |
| Favorable vs adverse | 1.21 (0.64-2.3) | 0.56 |
| Intermediate vs adverse | 1.17 (0.79-1.74) | 0.44 |
BSC: best supportive care; CI: confidence interval; CR: complete response; ELN: European LeukemiaNet; HR: hazard ratio; IT: intensive therapy; NIT: non-intensive therapy; NCR: no complete response; OS: overall survival; RR-AML: relapsed/refractory acute myeloid leukemia.